Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Study to Evaluate Pharmacokinetics, Efficacy and Safety of CT-P13 Subcutaneous in Patients With Active Crohn's Disease and Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has active Crohn's disease with a score on the Crohn's disease activity index between 220 and 450 points.~* Patient has active Ulcerative colitis as defined by a total Mayo score between 6 and 12 points (Part 2 only).~Exclusion Criteria:~* Patient who has previously received a biological agent for the treatment of CD and UC and/or a tumor necrosis factor-alpha (TNFα) inhibitor for the treatment of other disease~* Patient who has allergies to any of the excipients of infliximab or any other murine and/or human proteins or patient with a hypersensitivity to immunoglobulin product~* Patient who has a current or past history of infection with HIV, hepatitis B, or hepatitis C (carriers of hepatitis B and hepatitis C are not permitted to enrol into the study, but past hepatitis B resolved can be enrolled)~* Patient who has acute infection requiring oral antibiotics within 2 weeks or parenteral injection of antibiotics within 4 weeks prior to the first administration of the study drug, other serious infection within 6 months prior to the first administration of study drug or recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior to the first administration of the study drug~* Patient who has an indeterminate result for interferon-γ release assay (IGRA) or latent tuberculosis (TB) at Screening. For Part 2, if IGRA result is indeterminate at Screening, 1 retest will be possible during the screening. If the repeated IGRA result is negative, the patient can be included in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: CT-P13 IV 5 mg/kg (Type: ACTIVE_COMPARATOR): CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks (Part 1)
- Cohort 2: CT-P13 SC 120 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 120 mg by SC injection every 2 weeks (Part 1)
- Cohort 3: CT-P13 SC 180 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 180 mg by SC injection every 2 weeks (Part 1)
- Cohort 4: CT-P13 SC 240 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), 240 mg by SC injection every 2 weeks (Part 1)
- Arm 1: CT-P13 SC 120/240 mg (Type: EXPERIMENTAL): CT-P13 SC (Infliximab), either 120 mg or 240 mg every 2 weeks by SC injection (Part 2)
- Arm 2: CT-P13 IV 5 mg/kg (Type: ACTIVE_COMPARATOR): CT-P13 IV (Infliximab), 5 mg/kg by IV infusion every 8 weeks up to Week 22. CT-P13 IV was switched to either 120 mg or 240 mg of CT-P13 SC (Infliximab) treatment, and further doses with CT-P13 SC were given up to Week 54. (Part 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).